ESSEC

AKWEL: CURRENT OPERATING INCOME OF €30.2M FOR THE HY 2023

Retrieved on: 
Thursday, September 21, 2023
Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Plastic, Table tennis rubber, WCR, International business strategy, Investment, ESSEC, Growth, HGV, Law, Video game, Engineering

Gross operating surplus was up by 15.8% to €49.0m, and current operating income rose by 70.6% to €30.2m.

Key Points: 
  • Gross operating surplus was up by 15.8% to €49.0m, and current operating income rose by 70.6% to €30.2m.
  • With a financial income of -€2.5m and a tax expense representing €8.5m, the net income Group share stood at €19.2m for the half-year.
  • The Group’s net cash position, including debts on lease obligations, at 30 June 2023 was €91.5m.
  • The Group announces the appointment of Benoit Coutier to the position of Chief Financial Officer on October 1, 2023.

BRANFORD CASTLE PARTNERS SURGES AHEAD: ANNOUNCES PROMOTIONS AND NEW HIRES AS IT LOOKS TO THE FUTURE

Retrieved on: 
Thursday, September 14, 2023
University, Network, Marketing, Senior advisor, MBA, Wharton School of the University of Pennsylvania, Investment, Widener University Commonwealth Law School, ESSEC, Growth, Wesleyan theology

NEW YORK, Sept. 14, 2023 /PRNewswire/ -- In a major investment in its future, Branford Castle Partners has announced two internal promotions and two new hires as it positions itself for future growth.

Key Points: 
  • NEW YORK, Sept. 14, 2023 /PRNewswire/ -- In a major investment in its future, Branford Castle Partners has announced two internal promotions and two new hires as it positions itself for future growth.
  • Ben Sebel, a Senior Advisor of the firm, has increased and extended his time commitment to Branford as it looks forward to completing its Fund II investing and raising new capital for its anticipated Fund III.
  • Prior to joining Branford, Mr. Francis had held positions in management consulting and marketing analysis.
  • "Branford Castle Partners is a pre-eminent private equity firm focused on the lower middle market," said John S. Castle, President and CEO of the firm.

Didier Landais is appointed 4P-Pharma's CEO to lead the company into a new chapter of its development

Retrieved on: 
Tuesday, September 5, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, IDM, Business development, Revitalize American Manufacturing and Innovation Act of 2013, Doctor of Philosophy, Molecular and Cellular Biology, Cell therapy, Multimedia, Genome, History, Seal Rock, Patient, CBO, Growth, Fine chemical, Marketing, Management, Sanofi, ESSEC

During the latest strategic board meeting, the appointment of Didier Landais as the new CEO of 4P-Pharma was confirmed.

Key Points: 
  • During the latest strategic board meeting, the appointment of Didier Landais as the new CEO of 4P-Pharma was confirmed.
  • View the full release here: https://www.businesswire.com/news/home/20230905514097/en/
    Founded in 2014 by Revital Rattenbach, 4P-Pharma is entering a new era of its development.
  • On September 1st, 2023, Didier Landais succeeds Revital Rattenbach as CEO of 4P-Pharma.
  • As CEO, Didier Landais holds the responsibility for the company's overall strategy in terms of science, partnerships, and external growth.

LEO Pharma announces changes to its Global Leadership Team

Retrieved on: 
Monday, August 28, 2023
General Health, Pharmaceutical, Health, Other Health, Global leadership, Corporate Affairs, Leo Pharma, Culture, MBA, McKinsey & Company, Novartis, INSEAD, LEO, ESSEC, ESG, Family, Skin, Management, Pharmaceutical industry

Today, LEO Pharma announced the appointment of Nathalie Daste as new Executive Vice President, Global People and Corporate Affairs, and member of its Global Leadership Team, effective October 1, 2023.

Key Points: 
  • Today, LEO Pharma announced the appointment of Nathalie Daste as new Executive Vice President, Global People and Corporate Affairs, and member of its Global Leadership Team, effective October 1, 2023.
  • In her new role, Nathalie Daste will head LEO Pharma’s Global People function as well as Corporate Affairs, including sustainability and ESG.
  • Her vast experience from global life-science makes her a catch for LEO Pharma as we have been looking for a successor to Dennis Schmidt Pedersen.
  • With her joining the Global Leadership team, we can ensure these insights are brought into strategy.

Glion Institute of Higher Education and ESSEC Business School launch a new program: the Global Executive Master's in Hospitality Leadership

Retrieved on: 
Wednesday, January 25, 2023
Globally Executable MHP, Heart, School, Glion, Marketing, Glion Institute of Higher Education, Student, QS World University Rankings, QS, Partnership, Acceleration, ESSEC Business School, ESSEC, Teaching, Education, Traveller Alien Module 4: Zhodani, Management, Nursing

MONTREUX, Switzerland and PARIS-LA DEFENSE, Jan. 25, 2023 /PRNewswire/ -- Glion Institute of Higher Education, a benchmark business school specializing in hospitality and luxury professions; and ESSEC Business School, a leading management institution, are joining forces to offer a Global Executive Master's degree in Hospitality Leadership.

Key Points: 
  • MONTREUX, Switzerland and PARIS-LA DEFENSE, Jan. 25, 2023 /PRNewswire/ -- Glion Institute of Higher Education, a benchmark business school specializing in hospitality and luxury professions; and ESSEC Business School, a leading management institution, are joining forces to offer a Global Executive Master's degree in Hospitality Leadership.
  • Founded in Switzerland, Glion Institute of Higher Education celebrated its 60th anniversary in 2022.
  • The Global Executive Master's in Hospitality Leadership will welcome its first participants in November 2023.
  • Vincenzo Vinzi, Dean and President ESSEC Business School commented, "Thanks to this excellence-driven partnership, ESSEC is strengthening its expertise and academic offering in the field of hospitality.

Glion Institute of Higher Education and ESSEC Business School launch a new program: the Global Executive Master's in Hospitality Leadership

Retrieved on: 
Wednesday, January 25, 2023
Globally Executable MHP, Heart, School, Glion, Marketing, Glion Institute of Higher Education, Student, QS World University Rankings, QS, Partnership, Acceleration, ESSEC Business School, ESSEC, Teaching, Education, Traveller Alien Module 4: Zhodani, Management, Nursing

MONTREUX, Switzerland and PARIS-LA DEFENSE, Jan. 25, 2023 /PRNewswire/ -- Glion Institute of Higher Education, a benchmark business school specializing in hospitality and luxury professions; and ESSEC Business School, a leading management institution, are joining forces to offer a Global Executive Master's degree in Hospitality Leadership.

Key Points: 
  • MONTREUX, Switzerland and PARIS-LA DEFENSE, Jan. 25, 2023 /PRNewswire/ -- Glion Institute of Higher Education, a benchmark business school specializing in hospitality and luxury professions; and ESSEC Business School, a leading management institution, are joining forces to offer a Global Executive Master's degree in Hospitality Leadership.
  • Founded in Switzerland, Glion Institute of Higher Education celebrated its 60th anniversary in 2022.
  • The Global Executive Master's in Hospitality Leadership will welcome its first participants in November 2023.
  • Vincenzo Vinzi, Dean and President ESSEC Business School commented, "Thanks to this excellence-driven partnership, ESSEC is strengthening its expertise and academic offering in the field of hospitality.

Denis DELVAL is appointed President of the Ethypharm Group

Retrieved on: 
Monday, October 10, 2022
LinkedIn, Bayer, Supervisory board, INSEAD, ESSEC, Senior, ALK, Marketing, LFB, Group, CEO, CNS, Central nervous system, Pharmaceutical industry, Pharmacy

SAINT-CLOUD, France, Oct. 10, 2022 /PRNewswire/ -- The Supervisory Board appointed Denis DELVAL as CEO of the Ethypharm Group. 

Key Points: 
  • SAINT-CLOUD, France, Oct. 10, 2022 /PRNewswire/ -- The Supervisory Board appointed Denis DELVAL as CEO of the Ethypharm Group.
  • In 2017, he was appointed President of LFB, a biopharmaceutical group that develops, manufactures and markets medicinal products derived from living matter.
  • I look forward to mobilising energies and continuing the development of the Group", Denis DELVAL announced.
  • Ethypharm is a European pharmaceutical company specialising in two areas: the Central Nervous System and Hospital Injectable Medicines.

Important notice regarding participation at the 2022 Richemont Annual General Meeting

Retrieved on: 
Monday, August 15, 2022
Richemont, Woman, Gap, Tiger Brands, IMD, Fund of funds, Board of directors, CEO, Association, Infrastructure Development Bank of Zimbabwe, Board, Hotel manager, Annual, Attention, Independent, European, Financial compensation, AGM, Compagnie Financière Edmond de Rothschild, Company, Mission statement, World Rugby, Energy, LVMH, Season, JSE Limited, REDI (Execution Management System), City and Industrial Development Corporation, Industrialisation, Bluebell, Four Seasons Hotels and Resorts, Castle Grande, German company law, Professional Football Compensation Committee, ESSEC, Bridging the Gap, Time, Watch, Non-executive director, Person, Security (finance), Management, Holding company, Telkom, Group, Tiffany, Bulgari

He served with incomparable distinction as Richemont's Deputy Chairman for 22 years, from the Company's foundation in 1988 till 2010.

Key Points: 
  • He served with incomparable distinction as Richemont's Deputy Chairman for 22 years, from the Company's foundation in 1988 till 2010.
  • On behalf of the Board, I wish to thank each of them for their insightful and valuable support.
  • Full details of the proposals submitted to shareholders are set out in the formal Notice of Meeting.
  • The Board considers that all these resolutions are in the best interests of the Company and its shareholders as a whole.

LinKinVax Puts Together a Highly Experienced Team From the World of Biopharmaceuticals to Lead the Clinical Development and Upscaling of Its Vaccine Platform

Retrieved on: 
Thursday, May 19, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, Chemistry, GSK, MBA, Knowledge, Health, Kellogg-HKUST Executive MBA Program, R, Public health, Toxicology, Functional presence engine, Infection, CSR, Lists of television programs, Vaccine, COVID-19, Quality control, DESS, Pharmacy, Health care, CMC, Hasna Begum, Engineering, CRO, Paris-Sud University, Technology, Biomarker, Ministry of Education (Malaysia), ESSEC, CMO, HIV, Amgen, Cancer, Neutralizing antibody, Innovation, Pharmaceutical industry, Management, Eurofins Scientific, Audencia Business School, Protein structure

We are delighted to welcome these four experts in healthcare product development.

Key Points: 
  • We are delighted to welcome these four experts in healthcare product development.
  • Their sound knowledge and extensive experience of the biopharmaceuticals industry will provide invaluable support for the various clinical stages of our drug candidates.
  • She has developed and registered drugs on a global scale and acquired in-depth knowledge of sterile injectables.
  • Alexandra holds a doctorate in pharmacy from Paris V University and an Executive MBA in Healthcare Management from IAE Sorbonne Business School.

Tribun Health is Entering the Pharmaceutical and Drug Development Market to Meet the Challenges of Precision Medicine

Retrieved on: 
Tuesday, April 26, 2022
Drug development, CEO, Itech, PPD, Adoption, Clinical trial, Digital pathology, Pathology, MBA, VP, ESSEC, Histology, IMS, Leadership, Drug discovery, GLOBE, Machine learning, Patient, Macro, Neoplasm, California Healthcare Institute, ICON, Trial of the century, Sanofi, Peer review, Laboratory, Solution, CRO, Business, Optum, AI, Algorithm, Marketing, Business development, Industry, Acquisition, Risk, Precision medicine, Knowledge, Pharmaceutical industry, Medical imaging, Pharma, Biotechnology

Tribun Health looks forward to leveraging Loic's experience and success to develop the important and expanding pharmaceutical market.

Key Points: 
  • Tribun Health looks forward to leveraging Loic's experience and success to develop the important and expanding pharmaceutical market.
  • Tribun Health has a successful track record of providing solutions to the preclinical pharmaceutical and biotech market.
  • This will contribute to new drug development, accelerating drug discovery, reducing risk on clinical trials' endpoints, and fostering the rise of companion diagnosis," says Jean-Franois Pomerol , CEO at Tribun Health.
  • Tribun Health's extensive, decade-long expertise drives confidence for laboratories looking for a seamless transition to a digital pathology platform.